Detection of kinase domain mutations in BCR:: ABL1 leukemia by ultra-deep sequencing of genomic DNA
R Sánchez, S Dorado, Y Ruíz-Heredia… - Scientific reports, 2022 - nature.com
The screening of the BCR:: ABL1 kinase domain (KD) mutation has become a routine
analysis in case of warning/failure for chronic myeloid leukemia (CML) and B-cell precursor …
analysis in case of warning/failure for chronic myeloid leukemia (CML) and B-cell precursor …
Asciminib antagonizes transplantable BCR:: ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells
N Chatain, J Baumeister, MA Szymanski de Toledo… - Leukemia, 2024 - nature.com
Philadelphia chromosome-positive (Ph+) lymphoid blast crisis (BC), emanating from chronic
myeloid leukemia (CML), is a fatal disease with limited treatment options. Asciminib …
myeloid leukemia (CML), is a fatal disease with limited treatment options. Asciminib …
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single …
A Duminuco, U Markovic, NL Parrinello… - Frontiers in …, 2023 - frontiersin.org
Blinatumomab is a bispecific anti-CD3 and anti-CD19 antibody that acts as a T-cell engager:
by binding CD19+ lymphoblasts, blinatumomab recruits cytotoxic CD3+ T-lymphocytes to …
by binding CD19+ lymphoblasts, blinatumomab recruits cytotoxic CD3+ T-lymphocytes to …
[HTML][HTML] BCR:: ABL1 阳性急性B 淋巴细胞白血病分型与预后评估进展
闫宇辰， 王成， 糜坚青， 王瑾 - Chinese Journal of Hematology, 2024 - pmc.ncbi.nlm.nih.gov
酪氨酸激酶抑制剂和免疫靶向药物的应用已经明显改变了BCR:: ABL1 阳性急性B
淋巴细胞白血病的治疗策略和临床结果. 2022 年, 世界卫生组织(WHO) 和国际共识分型(ICC) …
淋巴细胞白血病的治疗策略和临床结果. 2022 年, 世界卫生组织(WHO) 和国际共识分型(ICC) …
Droplet digital polymerase chain reaction improves the detection of BCR‐ABL1 kinase domain mutation in Philadelphia chromosome‐positive acute lymphoblastic …
L Wan, J Ma, X Gong, Q Li, Y Wang… - International Journal …, 2023 - Wiley Online Library
Introduction Sanger sequencing (SS) is the most frequently used method for detecting ABL1
kinase domain (KD) mutations in patients with Philadelphia chromosome‐positive acute …
kinase domain (KD) mutations in patients with Philadelphia chromosome‐positive acute …
Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy
Imatinib mesylate, a tyrosine kinase inhibitor, is the first choice in chronic myeloid leukemia
treatment. However, resistance to imatinib may develop with time and in some cases …
treatment. However, resistance to imatinib may develop with time and in some cases …
Unravelling RecQ helicase function in genome stability using Strand-seq
Z Hamadeh - 2022 - open.library.ubc.ca
Helicases are a highly conserved family of motor proteins responsible for interacting with
and unwinding canonical and non-canonical DNA and RNA structures. The RecQ class of …
and unwinding canonical and non-canonical DNA and RNA structures. The RecQ class of …
[PDF][PDF] Delphi consensus on recommendations for the clinical management of Ph+ acute lymphoblastic leukemia patients Consenso Delphi de las recomendaciones …
JM Ribera, MT Gómez-Casares, R Ayala-Díaz… - Sangre (Eng …, 2023 - researchgate.net
La leucemia linfoblástica aguda (LLA) con cromosoma Filadelfia (LLA Ph+) es una
enfermedad con particularidades que le confieren un pronóstico adverso. El desarrollo de …
enfermedad con particularidades que le confieren un pronóstico adverso. El desarrollo de …